Cogent Biosciences, Inc. (COGT)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 16
in 89 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Cogent Biosciences’ net loss widened year over year in the third fiscal quarter of 2026, based on preliminary results reported , with net income of -$111.4 million down 37.7% from -$80.9 million a year ago. The company posted an operating loss of -$117.2 million as it continued advancing its precision-medicine pipeline, including CGT9486 for systemic mastocytosis and gastrointestinal stromal tumors. Cash usage remained elevated, with negative operating cash flow of -$80.8 million for the quarter.
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector developing precision medicines for genetically defined diseases. Trading as COGT on the NASDAQ Global Select Market, it is an early-stage biotech founded in 2014 and based in Waltham, Massachusetts.
Today's Snapshot
COGT ended the day slightly lower at 27.81, while its sector was weaker.
Trading Volume
Above 10d avg 2.4M
2.7M
vs S&P 500 Today
Moderate Outperformance
+0.12%
Updated: November 18, 2026 at 21:19 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$29.16 - $34.51Sell
- RSI (14)39.29Neutral
- Stochastic %K (14, 3, 3)13.79Buy
- MACD Level (12, 26)-0.85Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.